BMS Taps Immunai’s AI Immune Atlas To Decode Clinical Trial Responses
Immunai has entered a strategic collaboration with Bristol Myers Squibb (BMS) to apply its AI-powered operating system, AMICA-OS, in support of BMS’s clinical development programs. The partnership focuses on leveraging Immunai’s immune-mapping infrastructure and analytical models to generate insights from clinical immune data, particularly for areas such as mechanism-of-action analysis, patient stratification, and biomarker identification.
The platform, AMICA-OS, integrates multiomic single-cell data with AI models trained on one of the largest immune datasets, AMICA (Annotated Multiomic Immune Cell Atlas). In this collaboration, Immunai will process and analyze immune profiles from BMS clinical trials to help identify variations in patient responses and uncover immune-related biological patterns relevant to therapeutic development. The agreement includes the potential to expand into additional programs depending on outcomes.
The Bristol Myers Squibb partnership extends Immunai’s ongoing efforts to scale its immune system modeling across both commercial and academic programs. A day prior, Immunai selected researchers at Mount Sinai, Weill Cornell Medicine, and Massachusetts General Hospital to receive free single-cell multi-omic profiling. These projects, spanning autoimmune kidney disease, solid tumors, and cell therapy, will feed into AMICA—Immunai’s annotated immune cell atlas composed of harmonized single-cell data across over 800 cell types and 500 diseases. The resulting datasets will support Immunai’s AI engine, IDE (ImmunoDynamics Engine), which links immune cell behavior to treatment response and enables biomarker discovery, stratification, and clinical hypothesis generation.
Recent BMS partnerships combine external AI platforms with the company’s oncology and immunology portfolio. In small-molecule discovery, BMS is already working with Terray Therapeutics, which reported an AI-enabled milestone in a multi-target collaboration that applies its EMMI platform and a 13-billion-plus binding dataset to accelerate lead identification, and with AI Proteins in a deal of up to $400 million to design de novo therapeutic miniproteins for undisclosed targets. On the biologics side, BMS has entered a global partnership with BioNTech around BNT327, a bispecific antibody in late-stage trials for multiple solid tumors, and signed a multi-year collaboration with Harbour BioMed to discover next-generation multispecific antibodies with potential milestones exceeding $1 billion.
Topic: Industry Movers
